Creative Medical Technology Holdings Applauds Presidential Initiative to Expand IVF Access, Showcasing OvaStem® Program's Success and Growth Potential

About this update from Creative Medical Technology Holdings, Inc.

[{"type":"image","alt":"Creative Medical Technology Holdings, Inc.","displaySize":"","headline":null,"caption":"Creative Medical Technology Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":43,"url":"https://media.zenfs.com/en/globenewswire.com/4f20fc41994fc07ca8de61005b80d4fe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GXuNPn9qVk4jpjMkZ_nOOA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4f20fc41994fc07ca8de61005b80d4fe","width":300,"height":43}},"lazy":false},{"type":"text","content":"OvaStem® Demonstrates Strong Long-Term Efficacy with No Safety Concerns, Backed by Pending Orphan Drug Designation for AlloStem®","length":128,"tagName":"p"},{"type":"text","content":"PHOENIX, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ), a leading biotechnology innovator in regenerative medicine, enthusiastically supports President Donald J. Trump’s executive order expanding access to in vitro fertilization (IVF). This initiative directly aligns with the company’s vision to transform reproductive health through its groundbreaking OvaStem® program, which has demonstrated an 85% improvement in hormonal function and a 70% success rate in delivering healthy babies using a patient’s own eggs—all with no safety concerns at up to five years post-treatment.","length":623,"tagName":"p"},{"type":"text","content":"Patients with Primary Ovarian Insufficiency (POI) typically face only a 5-10% chance of spontaneous pregnancy and must rely on donor eggs for conception. OvaStem® changes this paradigm by leveraging the company’s rapid autologous therapy platform to harness the regenerative properties of a patient’s own cells, providing a novel, personalized alternative to traditional IVF. Further enhancing this breakthrough, the next-generation OvaStem® integrates the company’s AlloStem® platform, which is already being utilized in two FDA-cleared U.S. clinical trials. Additionally, Creative Medical Technology Holdings has filed for Orphan Drug Designation for POI, reinforcing its leadership in fertility innovation.","length":709,"tagName":"p"},{"type":"text","content":"The executive order, signed on February 18, 2025, mandates the Domestic Policy Council to deliver recommendations within 90 days to lower out-of-pocket IVF costs, which...

More updates from Creative Medical Technology Holdings, Inc.